ANNOVIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Annovis Bio, Inc. on Behalf of Annovis Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Annovis Bio, Inc. (Annovis or the Company) (NYSEAM: ANVS) on behalf of Annovis stockholders.
- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Annovis Bio, Inc. (Annovis or the Company) (NYSEAM: ANVS) on behalf of Annovis stockholders.
- Our investigation concerns whether Annovis has violated the federal securities laws and/or engaged in other unlawful business practices.
- Annovis is a clinical-drug company that develops drugs for the treatment of neurodegenerative diseases.
- Following this news, Annovis stock price declined $65.94 per share or over 60% to close at $43.50 on July 29, 2021.